评估胰腺癌易感性:ASCO临时临床意见
ASCO专家组系统检索1998年1月至2018年6月文献,针对胰腺腺癌易感人群的识别与管理提出临时临床意见:所有胰腺腺癌患者均应评估遗传性综合征风险,满足家族性胰腺癌标准者应进行遗传检测并讨论筛查利弊。
要点
- 所有胰腺腺癌患者均应评估与胰腺腺癌风险增加相关的遗传性综合征风险。
- 家族中有两名一级亲属患胰腺癌者符合家族性胰腺癌(FPC)标准,是遗传检测候选者。
- 即使家族史无异常,也可与胰腺癌患者讨论癌症易感性胚系遗传检测。
核心结论
- 所有胰腺腺癌患者均应评估与胰腺腺癌风险增加相关的遗传性综合征风险。
- 符合FPC标准、同一侧家族中有≥3例胰腺癌诊断或符合其他遗传性综合征标准者胰腺癌风险增加,是遗传检测候选者。
- 应与家族史符合FPC标准和/或遗传易感性者讨论胰腺癌筛查的获益与局限性。
研究设计与样本
- ASCO召集专家组,系统检索1998年1月至2018年6月发表的文献。
- 检索结果辅以系统综述和精选重要文献的参考文献手工检索及专家组成员整理文件的补充。
主要发现
- 家族中有两名一级亲属患胰腺癌者符合家族性胰腺癌(FPC)标准。
- 同一侧家族中有≥3例胰腺癌诊断者胰腺癌风险增加。
- 符合其他与胰腺癌风险增加相关的遗传性综合征标准者胰腺癌风险增加。
关键数值与推荐
- 所有胰腺腺癌患者均应进行遗传性综合征风险评估,包括全面回顾癌症家族史。
- 符合FPC标准、同一侧家族中≥3例胰腺癌诊断或符合其他遗传性综合征标准者,是遗传检测候选者。
- 即使家族史无异常,也可与胰腺腺癌患者讨论癌症易感性胚系遗传检测。
- 应与家族史符合FPC标准和/或遗传易感性者讨论胰腺癌筛查的获益与局限性。
临床怎么用
- 对所有胰腺腺癌患者评估遗传性综合征风险并全面回顾癌症家族史。
- 识别符合FPC标准、同一侧家族中≥3例胰腺癌诊断或符合其他遗传性综合征标准者,作为遗传检测候选者。
- 与胰腺腺癌患者讨论胚系遗传检测,即使家族史无异常。
- 与家族史符合FPC标准和/或遗传易感性者讨论胰腺癌筛查的获益与局限性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature published from January 1998 to June 2018. Results of the databases searched were supplemented with hand searching of the bibliographies of systematic reviews and selected seminal articles and contributions from Expert Panel members' curated files. PROVISIONAL CLINICAL OPINION: All patients diagnosed with pancreatic adenocarcinoma should undergo assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk should include a comprehensive review of family history of cancer. Individuals with a family history of pancreatic cancer affecting two first-degree relatives meet criteria for familial pancreatic cancer (FPC). Individuals (cancer affected or unaffected) with a family history of pancreatic cancer meeting criteria for FPC, those with three or more diagnoses of pancreatic cancer in same side of the family, and individuals meeting criteria for other genetic syndromes associated with increased risk for pancreatic cancer have an increased risk for pancreatic cancer and are candidates for genetic testing. Germline genetic testing for cancer susceptibility may be discussed with individuals diagnosed with pancreatic cancer, even if family history is unremarkable. Benefits and limitations of pancreatic cancer screening should be discussed with individuals whose family history meets criteria for FPC and/or genetic susceptibility to pancreatic cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
引用
- Stoffel EM, McKernin SE, Brand R, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2018. PMID: 30457921. doi:10.1200/JCO.18.01489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。